SLC5A2 and heart failure: Moreover, the final data from the EMPEROR-Preserved Phase III trial indicate that empagliflozin significantly reduces the risk of the composite of cardiovascular death or hospitalization for heart failure patients with preserved ejection fraction (HFpEF), with or without T2DM, indicating that the cardiovascular benefits of SGLT2 inhibitors are unlikely to be associated with improved glycemic control [3].